You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

CLINICAL TRIALS PROFILE FOR FLUTEMETAMOL F-18

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for FLUTEMETAMOL F-18

Subscribe to access the full database, or Subscribe
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01028053 ↗	Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease	Completed	i3 Research	Phase 3	2009-12-01	This study will investigate the efficacy of the Flutemetamol (18F) Injection PET tracer in identifying abnormal (18F) flutemetamol uptake patterns which predict the conversion from aMCI to a b-amyloid associated clinically probable Alzheimer's disease.
NCT01028053 ↗	Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease	Completed	i3 Statprobe	Phase 3	2009-12-01	This study will investigate the efficacy of the Flutemetamol (18F) Injection PET tracer in identifying abnormal (18F) flutemetamol uptake patterns which predict the conversion from aMCI to a b-amyloid associated clinically probable Alzheimer's disease.
NCT01028053 ↗	Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease	Completed	Medpace, Inc.	Phase 3	2009-12-01	This study will investigate the efficacy of the Flutemetamol (18F) Injection PET tracer in identifying abnormal (18F) flutemetamol uptake patterns which predict the conversion from aMCI to a b-amyloid associated clinically probable Alzheimer's disease.
NCT01028053 ↗	Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease	Completed	Quintiles, Inc.	Phase 3	2009-12-01	This study will investigate the efficacy of the Flutemetamol (18F) Injection PET tracer in identifying abnormal (18F) flutemetamol uptake patterns which predict the conversion from aMCI to a b-amyloid associated clinically probable Alzheimer's disease.
NCT01028053 ↗	Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease	Completed	GE Healthcare	Phase 3	2009-12-01	This study will investigate the efficacy of the Flutemetamol (18F) Injection PET tracer in identifying abnormal (18F) flutemetamol uptake patterns which predict the conversion from aMCI to a b-amyloid associated clinically probable Alzheimer's disease.
NCT01053312 ↗	PET Imaging of Brain Amyloid in Normal Pressure Hydrocephalus	Completed	i3 Statprobe	Phase 3	2009-12-01	This study will determine the level of association between the quantitative estimates of brain uptake of [18F]flutemetamol and the quantitative immunohistochemical estimates of amyloid levels in biopsy samples previously obtained during shunt placement in patients who have normal pressure hydrocephalus (NPH).
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for FLUTEMETAMOL F-18

Condition Name

Chart
Table

Condition Name for FLUTEMETAMOL F-18
Intervention	Trials
Alzheimer's Disease	8
Mild Cognitive Impairment	6
Dementia	2
Healthy	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for FLUTEMETAMOL F-18
Intervention	Trials
Alzheimer Disease	11
Cognition Disorders	8
Cognitive Dysfunction	8
Mild Cognitive Impairment	7
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for FLUTEMETAMOL F-18

Trials by Country

Map
Table

Trials by Country for FLUTEMETAMOL F-18
Location	Trials
United States	10
France	2
Switzerland	2
Netherlands	1
China	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for FLUTEMETAMOL F-18
Location	Trials
New Jersey	5
Utah	3
New York	1
Minnesota	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for FLUTEMETAMOL F-18

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for FLUTEMETAMOL F-18
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	8
Phase 2/Phase 3	2
[disabled in preview]	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for FLUTEMETAMOL F-18
Clinical Trial Phase	Trials
Completed	7
Terminated	5
Unknown status	3
[disabled in preview]	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for FLUTEMETAMOL F-18

Sponsor Name

Chart
Table

Sponsor Name for FLUTEMETAMOL F-18
Sponsor	Trials
GE Healthcare	8
i3 Statprobe	5
University of Utah	3
[disabled in preview]	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for FLUTEMETAMOL F-18
Sponsor	Trials
Industry	20
Other	14
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.